Targeting complete response with upfront bortezomib consolidation versus observation after the achievement of complete response following autologous transplantation for multiple myeloma (TUBA study)

By  

Hematological Oncology (Electronic), Vol. 36, Iss. 1, 2018-02 ,pp. : 202-209

John Wiley & Sons Inc

Access to resources Recommend Favorite

A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma

By Lewis Karl   Thompson John   Weber Jeffrey   Robinson William   O'Day Steven   Lutzky Jose   Legha Sewa   Floret Simon   Ruvuna Francis   Gonzalez Rene  

Investigational New Drugs, Vol. 24, Iss. 1, 2006-01 ,pp. : 89-94

Springer Publishing Company

Access to resources Recommend Favorite

Biosimilar Filgrastim in Autologous Peripheral Blood Hematopoietic Stem Cell Mobilization and Post-Transplant Hematologic Recovery

By  

Current Medicinal Chemistry, Vol. 23, Iss. 21, 2016-08 ,pp. : 2217-2229

Bentham Science Publishers

Access to resources Recommend Favorite

Safety of Efalizumab Therapy in Patients with Moderate to Severe Psoriasis: An Open-Label Extension of a Phase IIIb Trial

By Hamilton Tiffani  

Drug Safety, Vol. 31, Iss. 8, 2008-01 ,pp. : 715-726

Adis International

Access to resources Recommend Favorite

Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer

By Michael Michael   Gibbs Peter   Smith Robert   Godwood Alex   Oliver Stuart   Tebbutt Niall  

Investigational New Drugs, Vol. 27, Iss. 3, 2009-06 ,pp. : 253-261

Springer Publishing Company

Access to resources Recommend Favorite